Physician profile
Daniel Ilie
NPI 1962606103
$3,493.78
in general payments reported to CMS, 2019-2025
16 companies · $37.73 in 2025
The $37.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $302 · 2021: $576 · 2022: $334 · 2023: $1,491 · 2024: $498 · 2025: $37.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Travel and Lodging: $95.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.54 |
| Travel and Lodging | $95.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $797.40 | 2019-2025 | |
| Edwards Lifesciences Corporation | $764.10 | 2023 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $574.93 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $442.96 | 2019-2023 | Andexxa, Farxiga |
| Vifor Pharma, INC. | $282.49 | 2019-2021 | |
| Medtronic, INC. | $161.45 | 2023 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.28 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $82.81 | 2022-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $69.81 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $58.82 | 2023-2024 | Nuzyra |
| Glaxosmithkline, LLC. | $53.89 | 2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $40.06 | 2023 | Yupelri |
| Inari Medical, INC. | $22.58 | 2022 | |
| Allergan, INC. | $15.64 | 2020 | |
| Kestra Medical Technology Services, INC. | $13.57 | 2024 | Assure Wcd |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ilie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.